Appropriateness of Initial Therapy

The ECLIPSE trial, a pivotal, phase 3, multi-center, open-label, randomized clinical study, has met its primary end point in metastatic castration-resistant prostate cancer.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

ALLO-316 demonstrated a 50% overall response rate and 33% complete response rate in CD70-positive advanced RCC in the phase 1 TRAVERSE trial.

Neal Shore, MD, FACS, discussed a study on survival outcomes in metastatic castration-sensitive prostate cancer comparing apalutamide with abiraterone acetate.